AHCO at a glance
AdaptHealth Corp. (AHCO, SEC CIK 1725255) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on September 8, 2026 and Form 4 insider filings as recently as September 11, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), AdaptHealth Corp. (AHCO) reported revenue of $3.2 billion (down 0.5% from FY2024) and a net loss of $70.8 million. Diluted EPS was -$0.52.
- As of June 30, 2026, 34 institutional investment managers tracked by SignalX reported holding AdaptHealth Corp. (AHCO) shares worth $652.2 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by WOLF DALE B on August 7, 2026 of 20,000 shares at $5.86 per share.
- In the last 90 days, AHCO insiders reported 3 open-market purchases ($393K) and 0 open-market sales ($0) on Form 4, a net purchase of $393K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $3.2B
- −0.5% vs prior year
- Insiders · 90 days
- 3 buys · 0 sells
- Net +$393K
- 13F holders
- 34 funds
- $652.2M · −2 vs prior quarter
- Latest 8-K
- Sep 8, 2026
- Item 5.02 · Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Patient-centered healthcare-at-home solutions, including home medical equipment, medical supplies, and related services across four segments (Sleep, Respiratory, Diabetes, Wellness)
- Newly emphasized: Deployment of artificial intelligence (AI), including generative AI, for improving patient and operational workflows with associated regulatory risks highlighted
- Strategic shift: Increased focus on advanced technology platform integration and AI to enhance efficiency, compliance, and competitive positioning versus more manual competitors
- Notable quantitative metric: Serviced approximately 4.3 million patients annually through 640 locations in 48 states; approximately 10,900 employees as of December 31, 2025
- Distinctive fact: Outsourcing of about 4,400 full-time equivalent personnel for billing and administrative functions primarily in India and the Philippines
Risk Factors
- Regulatory risk: 2026 CMS Final Rule bundling payment for CGMs and insulin pumps starting January 1, 2028, may disrupt AdaptHealth's product coverage and reimbursement
- Macroeconomic risk: Inflation and rising interest rates could increase costs and interest expense on variable rate debt, impairing refinancing and cash flow
- Supply chain risk: Dependence on few suppliers for patient service equipment exposes AdaptHealth to price hikes, tariffs, and supply disruptions impacting revenue
- Competitive risk: Pharmacy benefit managers CVS Health and Optum, plus tech giants Amazon and Alphabet, entered HME market, threatening AdaptHealth’s referrals and revenue
- Financial risk: Capitated agreements with managed care payors pose risk if patient care expenses exceed prepaid fixed payments, impacting earnings
Management Discussion & Analysis
- Net revenue $3.24B in 2025, down 0.5% YoY from $3.26B in 2024, driven by $56.9M organic growth offset by $92.4M disposition decline
- Operating margin 2.8% in 2025 vs 8.1% in 2024; net loss $(70.8M) vs net income $90.4M; goodwill impairment $128M in 2025 vs $13.1M prior year
- Best performing segment Respiratory Health: revenue up 6.1% ($40M) to $691.2M; worst performing Wellness at Home: revenue down 9.8% ($63.1M) to $583.1M
- Cost of net revenue increased 2.2% to $2.64B; G&A expenses up 6.4% to $382.3M; depreciation down 9.8% to $40.6M; capital allocation details not provided
- Forward outlook highlights inflation risks impacting costs and demand; management leveraging purchasing power and technology for efficiencies; goodwill impairment risks remain
AI summary of the AHCO 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $740.3M, up 12.7% YoY from $657.1M
- Operating margin (18.6%) vs 10.0% YoY, reflecting $144.2M goodwill impairment
- Best segment Sleep Health revenue $386.5M, up 15.5% YoY
- Worst segment Wellness at Home revenue $159.4M, up 4.9% YoY
- Diabetes Health sale for $235.0M cash expected to close Q1 2027; inflation and cybersecurity incident remain headwinds
Risk Factors
- New divestiture risk triggered by July 19, 2026 Diabetes Health sale agreement
- Hart-Scott-Rodino review could delay or prevent closing targeted for first quarter 2027
- Divestiture proceeds may fall short of expectations, limiting planned debt repayment and core-business investment
- Buyer indemnification and transition-services obligations may constrain post-closing cost savings
- $325.0 million delayed-draw borrowing refinanced 6.125% Senior Notes, maturing April 2031
AI summary of the AHCO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Harriss Currie becomes CFO September 9, 2026, succeeding Jason Clemens after a one-day transition gap
- $670,000 annual salary and 100% target bonus, with 2026 bonus prorated subject to continued employment
Item EX-99.1: Item EX-99.1
- Harriss T. Currie appointed CFO effective September 9, 2026
- Jason Clemens transitioning out through October 1, 2026
Item 7.01: Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD, likely containing the substantive disclosure
- Disclosure not deemed “filed” under Exchange Act Section 18, limiting related liability exposure
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results covered quarter ended June 30, 2026
- Press release issued August 4, 2026 under Regulation FD
Item EX-99.1: Item EX-99.1
- Q2 revenue $740.3M, up 12.7%, with organic growth of 15.9% across all reportable segments
- Adjusted EBITDA $132.0M, down 3.2%, with margin declining to 17.8% from 20.8%
Item EX-99.1: Item EX-99.1
- Cardinal Health to acquire Diabetes Health for $235 million cash, subject to customary adjustments and regulatory approval
- Portfolio shift toward Sleep Health, Respiratory Health, and Wellness at Home businesses
AI summaries of AHCO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AHCO
Don't miss the next AHCO filing
- Alerts as it files. A push when AHCO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AHCO, by share count.
- Ask anything. An AI agent that reads every AHCO filing and answers with sources.
AHCO alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| CURRIE HARRISS T | A | Sep 9, 2026 | 141,372 | - |
| WOLF DALE B | Buy | Aug 7, 2026 | 20,000 | $5.86 |
| SAMET KENNETH A | Buy | Aug 6, 2026 | 23,500 | $6.38 |
| WOLF DALE B | Buy | Aug 6, 2026 | 20,000 | $6.30 |
| Schuster III Russell E. | Sell | Jul 1, 2026 | 11,275 | $10.44 |
| Weaver Susan T | A | Jun 24, 2026 | 18,999 | - |
| Lundberg Theodore B. | A | Jun 24, 2026 | 18,999 | - |
| Coppens Bradley J | A | Jun 24, 2026 | 18,999 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $3.2B | $3.3B | $3.2B |
| Operating Income | -$598.4M | $263.7M | $90.9M |
| Net Income | -$678.9M | $90.4M | -$70.8M |
| Op. Margin | -18.7% | 8.1% | 2.8% |
| Net Margin | -21.2% | 2.8% | -2.2% |
| Balance Sheet | |||
| Total Assets | - | $4.5B | $4.3B |
| Equity | - | $1.6B | $1.5B |
| ROE | - | 5.8% | -4.7% |
| Per Share | |||
| EPS | - | $0.61 | $-0.52 |
| Cash Flow | |||
| Operating CF | - | $541.8M | $601.8M |
| CapEx | $337.5M | $306.1M | $382.4M |
Source: XBRL data in AdaptHealth Corp. (AHCO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate AHCO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 34 | $652.2M |
| Q1 2026 | 36 | $710.3M |
| Q4 2025 | 27 | $573.3M |
| Q3 2025 | 29 | $512.6M |
| Q2 2025 | 28 | $537.1M |
| Q1 2025 | 27 | $415.4M |
| Q4 2024 | 23 | $339.9M |
| Q3 2024 | 20 | $212.5M |
- Dimensional Fund Advisors+749.0K (+11%)
- Renaissance Technologies LLC+536.0K (+235%)
- Principal Financial Group+520.9K (+19%)
- Ameriprise Financial+495.4K (+32%)
- Citadel Advisors LLC+355.5K (+275%)
- Goldman Sachs Group−562.1K (-50%)
- Millennium Management−313.3K (-47%)
- AQR Capital Management−204.6K (-21%)
- FMR LLC (Fidelity)−171.8K (-2%)
- Mangrove Partners−91.7K (-56%)
- Marex Group plc−30.0K
- U.S. Bancorp−60
Source: 13F-HR filings on SEC EDGAR (aggregated from 224 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AHCO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 11, 2026 | - | - | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 20, 2026 | - | Analysis | - |
| 8-K | Jul 7, 2026 | - | Analysis | - |
| 4 | Jul 6, 2026 | - | - | - |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 4 | May 29, 2026 | - | - | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 28, 2026 | - | - | - |
Related Health Care companies
- ADUS · Addus HomeCare CorpServices-Home Health Care Services
- AVAH · Aveanna Healthcare Holdings, Inc.Services-Home Health Care Services
- BTSG · BrightSpring Health Services, Inc.Services-Home Health Care Services
- CHE · Chemed CorpServices-Home Health Care Services
- EHAB · Enhabit, Inc.Services-Home Health Care Services
- OPCH · Option Care Health, Inc.Services-Home Health Care Services
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
AHCO SEC filings: frequently asked questions
Are AHCO insiders buying or selling?
In the last 90 days, AdaptHealth Corp. (AHCO) officers, directors and 10% owners reported 3 open-market purchases worth $393,130 by 2 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold AHCO stock?
As of June 30, 2026, the largest AdaptHealth Corp. (AHCO) holders among the 13F filers tracked by SignalX were BlackRock ($167.4 million), FMR LLC (Fidelity) ($82.1 million), Dimensional Fund Advisors ($79.9 million), Vanguard Portfolio Management LLC ($67.0 million), Vanguard Capital Management LLC ($50.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AHCO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), AdaptHealth Corp. (AHCO) reported revenue of $3.2 billion (down 0.5% from FY2024) and a net loss of $70.8 million. Diluted EPS was -$0.52. The figures come from the XBRL data in the 10-K.
What are the main risks in AHCO's latest 10-K?
In the 10-K filed February 24, 2026, AdaptHealth Corp. (AHCO) flagged: Regulatory risk: 2026 CMS Final Rule bundling payment for CGMs and insulin pumps starting January 1, 2028, may disrupt AdaptHealth's product coverage and reimbursement. Macroeconomic risk: Inflation and rising interest rates could increase costs and interest expense on variable rate debt, impairing refinancing and cash flow. (AI summary of the Risk Factors section.)
What did AHCO report in its latest 8-K?
AdaptHealth Corp. (AHCO) filed an 8-K on September 8, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 7.01 (Regulation FD Disclosure). Harriss Currie becomes CFO September 9, 2026, succeeding Jason Clemens after a one-day transition gap.
What are the latest AHCO SEC filings?
AdaptHealth Corp. (AHCO) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on September 8, 2026 and a Form 4 insider filing on September 11, 2026.
What is AHCO's SEC CIK number?
AdaptHealth Corp. (AHCO)'s SEC Central Index Key (CIK) is 1725255. EDGAR lists every AHCO filing under that number.
Ask anything about AHCO
The research agent reads AHCO's filings, financials, insider trades and 13F holders, then answers with sources.